AR113258A1 - Conjugados persistentes de derivados del péptido 2 similar al glucagón (glp-2) - Google Patents

Conjugados persistentes de derivados del péptido 2 similar al glucagón (glp-2)

Info

Publication number
AR113258A1
AR113258A1 ARP180102806A ARP180102806A AR113258A1 AR 113258 A1 AR113258 A1 AR 113258A1 AR P180102806 A ARP180102806 A AR P180102806A AR P180102806 A ARP180102806 A AR P180102806A AR 113258 A1 AR113258 A1 AR 113258A1
Authority
AR
Argentina
Prior art keywords
glp
glucagon
peptide
lysine
derivative
Prior art date
Application number
ARP180102806A
Other languages
English (en)
Spanish (es)
Inventor
Sung Youb Jung
In Young Choi
Min Young Kim
Jaehyuk Choi
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR113258A1 publication Critical patent/AR113258A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP180102806A 2017-09-28 2018-09-28 Conjugados persistentes de derivados del péptido 2 similar al glucagón (glp-2) AR113258A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20170126577 2017-09-28

Publications (1)

Publication Number Publication Date
AR113258A1 true AR113258A1 (es) 2020-03-11

Family

ID=65902619

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102806A AR113258A1 (es) 2017-09-28 2018-09-28 Conjugados persistentes de derivados del péptido 2 similar al glucagón (glp-2)

Country Status (22)

Country Link
US (3) US11530249B2 (cg-RX-API-DMAC7.html)
EP (1) EP3689898B1 (cg-RX-API-DMAC7.html)
JP (2) JP7751381B2 (cg-RX-API-DMAC7.html)
KR (2) KR102681143B1 (cg-RX-API-DMAC7.html)
CN (1) CN111433221B (cg-RX-API-DMAC7.html)
AR (1) AR113258A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018339210B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020006189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3084326A1 (cg-RX-API-DMAC7.html)
DK (1) DK3689898T3 (cg-RX-API-DMAC7.html)
EA (1) EA202090571A1 (cg-RX-API-DMAC7.html)
ES (1) ES3075688T3 (cg-RX-API-DMAC7.html)
FI (1) FI3689898T3 (cg-RX-API-DMAC7.html)
IL (1) IL273528B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004453A (cg-RX-API-DMAC7.html)
PH (1) PH12020550105A1 (cg-RX-API-DMAC7.html)
PT (1) PT3689898T (cg-RX-API-DMAC7.html)
SA (1) SA520411644B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202002563WA (cg-RX-API-DMAC7.html)
TW (2) TWI794897B (cg-RX-API-DMAC7.html)
WO (1) WO2019066586A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202001888B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
EP4082561A4 (en) * 2019-12-24 2024-02-07 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating metabolic bone diseases, comprising glp-2 or conjugate thereof
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
CN115697375A (zh) * 2020-04-03 2023-02-03 韩美药品株式会社 预防或治疗放疗、化疗或其组合引发的粘膜炎的包含glp-2衍生物或其长效缀合物的药物组合物
IL298298A (en) 2020-05-22 2023-01-01 Hanmi Pharm Ind Co Ltd A liquid formulation of a long-acting conjugate of glp–2
CA3182260A1 (en) 2020-06-09 2021-12-16 Gleb Feldman Manufacture, formulation and dosing of apraglutide
CA3201916A1 (en) * 2020-12-24 2022-06-30 Hanmi Pharm. Co., Ltd. Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome
US20250276044A1 (en) * 2022-04-18 2025-09-04 Hanmi Pharm. Co., Ltd. COMBINATION THERAPY COMPRISING GLP-2, AND INSULINOTROPIC PEPTIDE, TNFa INHIBITOR, OR BOTH FOR PREVENTING OR TREATING BOWEL DISEASE
JP2026501948A (ja) 2022-12-23 2026-01-19 ハンミ ファーマシューティカル カンパニー リミテッド Glp-2誘導体又はその持続型結合体を含む移植片対宿主病の予防又は治療用薬学的組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
DK1360202T3 (da) * 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
US20090238838A1 (en) * 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
ES2347902T3 (es) * 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
DE602006020123D1 (de) * 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
KR101746686B1 (ko) * 2010-10-26 2017-06-15 한미사이언스 주식회사 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―2(glp―2)약물 결합체
ES2687651T3 (es) * 2011-09-12 2018-10-26 Amunix Operating Inc. Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체

Also Published As

Publication number Publication date
US20230090790A1 (en) 2023-03-23
IL273528B2 (en) 2025-08-01
BR112020006189A2 (pt) 2020-10-13
US20200262888A1 (en) 2020-08-20
NZ762962A (en) 2024-07-05
ES3075688T3 (en) 2026-08-06
EP3689898A4 (en) 2021-06-16
CN111433221B (zh) 2024-12-27
EP3689898B1 (en) 2026-04-29
US20220251164A1 (en) 2022-08-11
TWI794897B (zh) 2023-03-01
PT3689898T (pt) 2026-07-16
FI3689898T3 (fi) 2026-07-21
KR102681144B1 (ko) 2024-07-04
KR20190037181A (ko) 2019-04-05
JP7751381B2 (ja) 2025-10-08
US12703730B2 (en) 2026-08-11
ZA202001888B (en) 2021-05-26
JP2020534840A (ja) 2020-12-03
AU2018339210B2 (en) 2023-02-02
SA520411644B1 (ar) 2024-02-25
TWI795443B (zh) 2023-03-11
IL273528B1 (en) 2025-04-01
TW202142560A (zh) 2021-11-16
EP3689898A1 (en) 2020-08-05
MX2020004453A (es) 2020-07-24
DK3689898T3 (da) 2026-07-27
KR102681143B1 (ko) 2024-07-04
KR20240013836A (ko) 2024-01-30
PH12020550105A1 (en) 2020-12-07
WO2019066586A1 (ko) 2019-04-04
US11530249B2 (en) 2022-12-20
AU2018339210A1 (en) 2020-04-16
TW201927806A (zh) 2019-07-16
CN111433221A (zh) 2020-07-17
JP2023138505A (ja) 2023-10-02
CA3084326A1 (en) 2019-04-04
SG11202002563WA (en) 2020-04-29
IL273528A (en) 2020-05-31
EA202090571A1 (ru) 2020-07-30

Similar Documents

Publication Publication Date Title
HRP20240016T1 (hr) Konjugati polipeptida interleukina-2 i njihove uporabe
AR121587A2 (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
FI3299383T3 (fi) Vasta-aineen erityinen modifikaatio igg-sitoutuvalla peptidillä
EP4494710A3 (en) Pharmaceutical composition comprising an anti-her3 antibody-drug conjugate for use in treating breast cancers
MX2021006991A (es) Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
AR086660A1 (es) Composicion para el tratamiento de diabetes que comprende un conjugado de insulina de accion prolongada y conjugado de un peptido insulinotropico de accion prolongada
RU2017131285A (ru) Биоразлагаемые тиол-ен-полимеры и способы их получения
AR115516A2 (es) Formulación de acción prolongada de la hormona estimuladora de los folículos humana, métodos para prepararla y conjugado de dicha hormona
BRPI0309868B8 (pt) métodos de preparação de uma composição de reduzida fração conjugada inferior
CR20200595A (es) NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA LA LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0295)
CR20180398A (es) Péptidos, combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga y otros tipos de cáncer
PE20221909A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf
GEP20074016B (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
CR20180591A (es) Nuevos péptidos y nueva combinación de péptidos como dianas y para el uso en la inmunoterapia contra el cáncer de vesícula biliar y el colangiocarcinoma, así como otros tipos de cáncer
MX2021012740A (es) Péptidos y nanopartículas para entrega intracelular de moléculas.
CL2018000545A1 (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer.
IL273528B2 (en) Long-acting conjugates of glp-2 derivatives
RU2018120696A (ru) Конъюгаты анти-cd22 антитело-майтансин и способы их применения
PE20211499A1 (es) Peptidos restringidos por a 03 para el uso en la inmunoterapia contra el cancer y metodos relacionados
JP2019501214A5 (cg-RX-API-DMAC7.html)
US20230390409A1 (en) Fap-activated serum extended half-life therapeutic conjugates
CL2020002953A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer (divisional de la solicitud 201902878)
RU2017132324A (ru) Иммуноконъюгаты для специфической индукции цитотоксичности т-клеток против клеток-мишеней
AR109629A1 (es) Composiciones para la administración local de agonistas de receptores de tipo toll
PE20211740A1 (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer